Tirzepatide 10mg

Tirzepatide is a 39-amino acid synthetic peptide engineered as a dual agonist of the GLP-1 and GIP receptors. Its C20 fatty-diacid conjugation enables high-affinity albumin binding, extending plasma half-life to approximately five days and supporting once-weekly dosing protocols in research models.

• Dual receptor activation — simultaneous GLP-1 and GIP receptor agonism produces synergistic reductions in food intake and postprandial glucose excursions.
• Superior weight-reduction profile — Phase 3 SURMOUNT trial reporting up to −22.5% body weight versus placebo.
• Improved insulin sensitivity — activates GIP receptor-mediated pathways in adipocytes and skeletal muscle.
• Cardiovascular & lipid biomarkers — favourable effects on LDL-cholesterol, triglycerides, and systolic blood pressure.
• Long-acting pharmacokinetics — ~5-day half-life via fatty-acid conjugation.

⚠️ For research use only. Not for human or animal consumption. Store lyophilised powder at −20°C. Reconstitute with Bacteriostatic Water.